Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

European Journal of Pharmacology
Seyyed Mortaza HaghgooIan M Adcock

Abstract

Recent studies have been established high degree of genetic diversity in solid organ tumors among individuals and even between individual tumor cells. This intratumor and intertumor genetic diversity results in a heterogeneous tumor with unique characteristics which potentially allows effective drug therapy. The goal of pharmacogenomics is to elucidate the genetic network(s) that underlie drug efficacy and drug resistance. Advances in targeted and personalized therapy play an increasingly important role in many common cancers, notably lung cancer, due to the high incidence, prevalence, mortality and the greater tendency towards drug resistance seen in these patients. Non-small cell lung cancer (NSCLC) is characterized by mutations in the epidermal growth factor receptor (EGFR) and or downstream kinase pathways. This has led to the development of highly selective monoclonal antibodies and EGFR tyrosine kinase inhibitors (EGFR-TKIs) to prevent cancer initiation, proliferation, differentiation, angiogenesis, survival, and invasion. However, resistance to many of these new treatments is induced and further pharmacogenomic analysis has revealed mutations associated with increased or reduced drug efficacy. Combinations of kinase inhi...Continue Reading

References

Jun 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M BlumU A Meyer
Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·K P VatsisW W Weber
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·C BirchmeierM Wigler
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·L NagarajanC M Croce
Sep 1, 1986·Molecular and Cellular Biology·C BirchmeierM Wigler
Nov 23, 2000·Lancet·U A Meyer
Dec 4, 2001·Genes & Development·P W Ingham, A P McMahon
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jul 6, 2002·Science·I Bernard Weinstein
Jul 13, 2002·Journal of Cellular Physiology·M MacalusoA Russo
Feb 7, 2003·The New England Journal of Medicine·William E Evans, Howard L McLeod
Mar 1, 2003·Nature Genetics·Allan BalmainBruce Ponder
Sep 14, 1956·Science·A S ALVINGC E ICKES
Aug 13, 1960·British Medical Journal·D A EVANSV A McKUSICK
Jan 23, 2004·Nature Reviews. Cancer·Ricardo PardalSean J Morrison
Aug 23, 1952·Journal of the American Medical Association·C B CLAYMANA S ALVING
Mar 24, 2004·Cell·Paul T C WanUNKNOWN Cancer Genome Project
Apr 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·David J StewartPeter MacLeod
Oct 12, 2004·Annual Review of Cell and Developmental Biology·Catriona Y Logan, Roel Nusse
Nov 16, 2004·Molecular and Cellular Biology·David TulasneVéronique Fafeur
Feb 26, 2005·Journal of Cell Science·Krister WennerbergChanning J Der
Apr 15, 2005·Nature·Tannishtha Reya, Hans Clevers
Jul 30, 2005·Current Biology : CB·Natalia MitinChanning J Der
Oct 19, 2005·International Journal of Cancer. Journal International Du Cancer·Hisayuki Shigematsu, Adi F Gazdar
Dec 16, 2005·Neoplasia : an International Journal for Oncology Research·Yi-Shing ShiehCheng-Wen Wu
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lucio Miele
May 5, 2006·Proceedings of the National Academy of Sciences of the United States of America·Hongbin JiKwok-Kin Wong
Sep 5, 2006·Annual Review of Genomics and Human Genetics·Richard M Weinshilboum, Liewei Wang
Feb 24, 2007·Nature Reviews. Cancer·Sreenath V SharmaDaniel A Haber
May 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erminia MassarelliIgnacio I Wistuba
Dec 22, 2007·Nature Reviews. Cancer·Roberto ChiarleGiorgio Inghirami
Feb 28, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jenifer L MarksWilliam Pao
Aug 30, 2008·Experimental Cell Research·Sreenath V Sharma, Jeffrey Settleman
Sep 9, 2008·Trends in Molecular Medicine·Thomas KlonischMarek Los

❮ Previous
Next ❯

Citations

Feb 9, 2016·International Journal of Experimental Pathology·Xi ChenDabo Liu
Sep 16, 2016·Cancer Biology & Therapy·Huanxian ChenSimon Ming-Yuen Lee
Oct 23, 2016·Oncotarget·Andrew M OvermillerMỹ G Mahoney
May 1, 2021·International Journal of Molecular Sciences·Daniela FerreiraRaquel Chaves

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.